Abstract: A high-frequency magnetic field generator 2 applies microwave to a magnetic resonance member 1 capable of an electron spin quantum operation using the microwave. A magnet 3 applies a static magnetic field to the magnetic resonance member 1. An irradiating device 12 irradiates the magnetic resonance member 1 with light of a specific wavelength. A flux transformer 4 senses a measurement target magnetic field using a primary coil 4a and applies an application magnetic field corresponding to the sensed measurement target magnetic field to the magnetic resonance member 1 using a secondary coil 4b. Further, the magnetic resonance member 1 is arranged at a position in a hollow part of the secondary coil 4b of the flux transformer 4 and in a hollow part of the magnet 3.

Abstract: Provided are a flame-retardant non-aqueous electrolytic solution which exhibits good flame retardancy and has excellent cycle characteristics and electrical resistance characteristics, and a secondary battery using the flame-retardant non-aqueous electrolytic solution. The flame-retardant non-aqueous electrolytic solution according to the present invention contains at least a non-aqueous solvent and an electrolyte dissolved in the non-aqueous solvent, the non-aqueous solvent contains at least one of phosphoric acid esters of chemical formulae (1) to (3) below, the electrolyte contains at least one of a difluorophosphoric acid salt and a nitric acid salt, and the content of the phosphoric acid ester is 20 mass % or more with respect to the total mass of the flame-retardant non-aqueous electrolytic solution. In the formulae, X1 to X3 each independently represent a hydrocarbon group having 1 to 20 carbon atoms, or the like, and Y1 and Y2 each independently represent a halogen atom.

Abstract: Disclosed are: a method for producing a cell population containing regulatory T cells, the method comprising (1) culturing a cell population containing pluripotent stem cell-derived CD4+ T cells in the presence of at least one substance selected from the group consisting of a CDK8 and/or CDK19 inhibitor, a TNFR2 agonist, an mTOR inhibitor, and a TGF-?R agonist; a cell population containing regulatory T cells obtained by the method; and a medicine containing the cell population containing regulatory T cells.

Abstract: A method for observing a surface includes a) and b). At the a), a material including at least one or more solid luminescent dye molecules is accumulated in a region having an abnormal shape in a substrate or in a structure on the substrate. At the b), the region having the abnormal shape in the substrate or in the structure on the substrate is irradiated with illumination light to acquire the fluorescent image of the solid luminescent dye molecules.

Abstract: An object of the present invention is to provide an SiC ceramics having an excellent environmentally resistant coating. An SiC ceramics comprising a metal oxide, the SiC ceramics comprising a surface modification layer containing a silicate, the surface modification layer being derived from a raw material forming the SiC ceramics, which is a matrix.

Abstract: Provided are a hollow spherical particle that has higher safety and can be prepared more easily. A hollow spherical particle that is a self-assembled body of lignin, the lignin having a content of ?-O-4 ether type structure of 50% or more and a solubility in 60 to 80% ethanol at 25° C. of 2 w/v % or more.

Abstract: The present invention provides a drug for treating or preventing Charcot-Marie-Tooth disease, said drug comprising a compound represented by formula (I) (in formula (I), the symbols are as defined in the attached description) or formula (II) (in formula (II), the symbols are as defined in the attached description), or a salt of the compound.

Abstract: A blockchain network system includes a plurality of sensor devices and a blockchain network. The sensor devices are communicably connected with each other via the blockchain network, and sensor data acquired by the sensor devices is managed on the blockchain network in a distributed manner. The sensor device includes a sensor unit for sequentially acquiring sensor data in real space on a frame-by-frame basis, a data processing unit for processing the sensor data, a data storage unit for storing the sensor data, an encryption unit for encrypting the sensor data, and a registration unit for registering the sensor data encrypted by the encryption unit on the BC network. The data processing unit aggregates the sensor data with a predetermined number of frame aggregations. The encryption unit collectively encrypts the sensor data aggregated by the data processing unit with the predetermined number of frame aggregations.

Abstract: Disclosed is a method for producing T cells, the method comprising: (1) culturing three-dimensional cell aggregate(s) comprising cells that can differentiate into T cells, and stromal cells that express Notch ligand(s) derived from pluripotent stem cells. Also disclosed are T cells obtained by the method, and a medicine comprising the T cells.

Abstract: The present invention provides a therapeutic or prophylactic medicine for fragile X syndrome containing a compound represented by formula (I) (see the attached description for the symbols in formula (I)) or formula (II) (see the attached description for the symbols in formula (II)) or a salt thereof.

Abstract: According to one embodiment, a structure evaluation system of the embodiments includes a plurality of sensors, a position locator, and an evaluator. The plurality of sensors detect elastic waves. The position locator locates elastic wave sources on the basis of a plurality of elastic waves detected by each of the plurality of sensors. The evaluator evaluates a deterioration state of a structure in accordance with a presence or absence of a sensor and an elastic wave source distribution which shows a position of the elastic wave sources obtained on the basis of a result of locating of the elastic wave sources.

Abstract: Provided is a pharmaceutical composition for use in radiotherapy, comprising: a compound represented by formula (I) wherein R1 is an aryl group substituted with a substituent selected from an iodine atom and others, wherein the aryl group is optionally substituted with a substituent such as a hydroxy group, X represents a bond or the like and ring A is a group represented by formula (A), wherein R2 is a non-aromatic heterocyclic group optionally substituted with at least one C1-C4 alkyl group, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. Also, provided is a nanoparticle and a method for treating solid cancer using the compound.

Abstract: Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition comprises a retinoic acid receptor (RAR) agonist.

Abstract: A sleep apnea syndrome determination apparatus includes a processing unit configured to, by using RRI data indicating a heart rate interval (R-R Interval: RRI) in a sleeping period of a subject, determine whether or not the subject has sleep apnea syndrome. The processing unit operates to generate a feature vector including a plurality of heart rate intervals that are consecutive in the sleeping period; calculate, from a value that is outputted as a result of inputting the feature vector to a recurrent neural network and that is obtained for each identification target period that corresponds to the plurality of heart rate intervals included in the feature vector inputted, an index based on a ratio between a period of an apnea state and a period of a normal respiration state in the sleeping period; and determine whether the subject has sleep apnea syndrome, on the basis of the index.

Abstract: The present disclosure provides a thermoforming composition with etherified wood powder.

Abstract: This invention provides a peptide consisting of (i) the amino acid sequence LSSTOAOOSY (SEQ ID NO: 1), (ii) the amino acid sequence LSSTOAQQSW (SEQ ID NO: 6), or (iii) the amino acid sequence LSSTOAQQSF (SEQ ID NO: 7).

Abstract: Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.

Abstract: An object of the present invention is to provide a method for producing T cells or NK cells, a culture medium for culturing T cells or NK cells, a method for culturing T cells or NK cells, a method for maintaining the undifferentiated state of undifferentiated T cells, and a growth promoter for T cells or NK cells, which are capable of efficiently proliferating T cells or NK cells and maintaining the state of the cells (for example, undifferentiated property). The present invention relates to a method for producing T cells or NK cells including culturing T cells or NK cells in a culture medium containing a bisbenzylisoquinoline alkaloid represented by formula (X-1) or formula (X-2) or a compound resulting from cleavage of one ether bond thereof or a pharmaceutically acceptable salt thereof, and the like.

Abstract: Technical Problem The purpose of the present invention is to provide a method which enables sex selection in a non-human animal, and enables a coming individual to have no recombination gene, and a transgenic non-human animal giving birth to individuals of only one sex, which is used in the method. Solution to Problem The present disclosure relates to a male transgenic non-human animal in which one of an X chromosome and a Y chromosome comprises an exogenous embryonic death induction gene operatively connected to a drug-responsive promoter. The present disclosure also includes a method for producing a male transgenic non-human animal for sex selection.

Abstract: A brain measurement apparatus configured to generate an MR image and a brain's magnetic field distribution of a subject includes: an MRI module having a transmission coil configured to transmit a transmission pulse toward the subject and a detection coil configured to detect a nuclear magnetic resonance signal generated in the subject by the transmission pulse; an optically pumped magnetometer configured to detect a brain's magnetic field of the subject; a generator configured to generate the MR image based on the nuclear magnetic resonance signal detected by the detection coil and generating the brain's magnetic field distribution based on the brain's magnetic field detected by the optically pumped magnetometer; a marker displayed on the MR image generated by the generator; and a helmet-type frame to which the detection coil, the optically pumped magnetometer, and the marker are attached and which is attached to a head of the subject.